The goal of WP 2 is to replace the surface glycoprotein of rhabdovirus particles by recombinant PrP constructs. It is expected that the PrP envelope of recombinant virus-like particles is presented in an ordered quasi-crystalline and highly immunogenic form. The expression of rhabdovirus T helper cell determinants presumably will not be affected in virus-like particles.
The goal of WP 3 is to assess the efficacy of active and passive prion vaccination. In particular it will be analyzed whether immunotherapy is useful in preventing manifestation of severe and devastating clinical symptoms of prion disease in mice already harbouring prions in the periphery. Limitations of anti-PrP vaccination will be assessed by defining conditions leading to auto-immunity.
© 2005-2006 | Imprint